Cart
sales@molnova.com
Lorundrostat
CAS No. 1820940-17-7
Lorundrostat( —— )
Catalog No. M35665 CAS No. 1820940-17-7
Lorundrostat (MT-4129) is an aldosterone synthase inhibitor with antihypertensive activity that lowers systolic blood pressure.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 178 | Get Quote |
|
| 5MG | 275 | Get Quote |
|
| 10MG | 432 | Get Quote |
|
| 25MG | 821 | Get Quote |
|
| 50MG | 1122 | Get Quote |
|
| 100MG | 1485 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLorundrostat
-
NoteResearch use only, not for human use.
-
Brief DescriptionLorundrostat (MT-4129) is an aldosterone synthase inhibitor with antihypertensive activity that lowers systolic blood pressure.
-
DescriptionLorundrostat (MT-4129) is an orally activealdosterone synthaseinhibitor. Lorundrostat can be used in studies of high blood pressure.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1820940-17-7
-
Formula Weight451.56
-
Molecular FormulaC24H33N7O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 33.33 mg/mL (73.81 mM; Ultrasonic; (HCL ，pH≈2); )
-
SMILESCC(=O)N[C@H]1CC[C@@H](CC1)NC(=O)CN1CCN(CC1)c1nncc(n1)-c1ccc(C)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022.
molnova catalog
related products
-
(-)-Epiafzelechin
(-)-Epiafzelechin exhibits significant anti-inflammatory activity on carrageenin-induced mouse paw edema, it exhibits a dose-dependent inhibition on the COX activity with an IC50 value of 15 microM, it exhibits about 3-fold weaker inhibitory potency on the enzyme activity than indomethacin as a positive control.
-
Cinobufaginol
Cinobufaginol is a natural product.
-
Vilobelimab
Vilobelimab (CaCP-29, IFX-1), a monoclonal antibody targeting C5a, inhibits this pro-inflammatory complement component, which is pivotal in causing organ dysfunction.
